Breaking News Instant updates and real-time market news.

PFE

Pfizer

$44.34

0.06 (0.14%)

, PTCT

PTC Therapeutics

$43.58

-2.94 (-6.32%)

10:25
10/02/18
10/02
10:25
10/02/18
10:25

Credit Suisse biotech analysts to hold an analyst/industry conference call

Biotechnology Analysts discusses what to watch for at the 23rd International Annual Congress of the World Muscle Society (WMS), along with Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA) on an Analyst/Industry conference call to be held on October 2 at 11 am.

PFE

Pfizer

$44.34

0.06 (0.14%)

PTCT

PTC Therapeutics

$43.58

-2.94 (-6.32%)

SLDB

Solid Biosciences

$45.02

-1.36 (-2.93%)

SRPT

Sarepta

$141.92

-6.79 (-4.57%)

  • 02

    Oct

  • 03

    Oct

  • 03

    Oct

  • 10

    Oct

  • 17

    Oct

  • 22

    Oct

  • 30

    Oct

PFE Pfizer
$44.34

0.06 (0.14%)

09/12/18
ADAM
09/12/18
NO CHANGE
Target $87
ADAM
Buy
Exact Sciences price target raised to $87 from $72 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Exact Sciences (EXAS) as he updated his model to include the contribution of Pfizer (PFE) reps. Massaro, who believes the company is well positioned to expand its business and he raised his estimates, reiterated his Buy rating on Exact Sciences shares.
09/18/18
JPMS
09/18/18
NO CHANGE
Target $81
JPMS
Overweight
Market evolving favorably for Ascendis into Phase III results, says JPMorgan
JPMorgan analyst Jessica Fye believes the long-acting growth hormone deficiency competitive landscape is evolving favorably for Ascendis Pharma heading into the Phase III results for the company's TransCon growth hormone in Q1 of 2019. The past 12-24 months has brought emerging clinical issues for all three of the key long-acting competitors, Fye tells investors in a research note. These range from the failure of Versartis (VSAR) at the most extreme, to the missed pivotal trial in adults for Pfizer (PFE) and Opko (OPK), to results that may raise questions around efficacy for Novo (NVO) in adults, Fye contends. The analyst believes these create opportunity for Ascendis, assuming the company is successful in Phase III. She continues to have high conviction in the success of the Phase III trial and keeps an Overweight rating on Ascendis Pharma with an $81 price target.
10/01/18
JPMS
10/01/18
NO CHANGE
Target $46
JPMS
Overweight
Pfizer price target raised to $46 from $42 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Pfizer to $46 on a revisit of the company's story. The analyst sees a "meaningful shift" in the Pfizer narrative away from potential acquisitions to the company's organic growth prospects post the Lyrica patent expiration in 2019. While he expects the company's growth will slow in 2019/2020, he sees a "distinct re-acceleration" of sales and earnings growth for Pfizer in the 2021-2025 period. Schott believes shares of Pfizer can further re-rate if the Street gains further confidence in its "sustained topline growth and capital deployment opportunities." The analyst keeps an Overweight rating on the shares.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
PTCT PTC Therapeutics
$43.58

-2.94 (-6.32%)

07/20/18
WBLR
07/20/18
NO CHANGE
WBLR
Outperform
William Blair positive on PTC's acquisition of Agilis
William Blair analyst Raju Prasad views PTC Therapeutics' acquisition of Agilis Biotherapeutics favorably saying it diversifies the company's pipeline and provides it with a "unique CNS-focused gene therapy platform with several catalysts." Prasad keeps an Outperform rating on PTC Therapeutics.
07/24/18
SBSH
07/24/18
NO CHANGE
Target $50
SBSH
Buy
PTC Therapeutics price target raised to $50 from $35 at Citi
Citi analyst Joel Beatty raised his price target for PTC Therapeutics to $50 and maintains a Buy rating on the name. Continued growth in sales from the company's Duchenne muscular dystrophy franchise, especially Translarna outside the U.S., will contribute to push the stock higher, Beatty tells investors in a research note. The analyst also believes the data so far for RG7916 in type 1 spinal muscular atrophy patients suggests it is an effective drug and that further upside could come later this year. Further, he sees PTC's recent acquisition of gene therapy company Agilis as providing a high level of synergy.
09/28/18
JPMS
09/28/18
NO CHANGE
Target $51
JPMS
Neutral
PTC Therapeutics price target raised to $51 from $15 at JPMorgan
JPMorgan analyst Eric Joseph raised his price target for PTC Therapeutics to $51 heading into risdiplam clinical updates for both Type 1 and Type 2/3 spinal muscular atrophy at World Muscle next week. The analyst sees 15% share swings on definitively positive and negative data. Joseph believes the World Muscle conference creates incremental upside potential but that longer term appreciation is based on execution. He keeps a Neutral rating on PTC Therapeutics.
10/01/18
CANT
10/01/18
INITIATION
Target $66
CANT
Overweight
PTC Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started PTC Therapeutics with an Overweight rating and $66 price target.
SLDB Solid Biosciences
$45.02

-1.36 (-2.93%)

06/19/18
JPMS
06/19/18
NO CHANGE
Target $29
JPMS
Underweight
JPMorgan says 'outsized' move in Solid Biosciences leaves material downside risk
JPMorgan analyst Anupam Rama does not deny that Sarepta's (SRPT) micro-dystrophin data establishes proof-of-concept for the space and there should be a positive read-through for Solid Biosciences (SLDB). However, Rama thinks the move up in Solid has been "outsized," leaving material downside risk, given that Solid noted just yesterday that the first update from the SGT-001 MD program will be in potentially more than 12 months out. Also being underappreciated is that Sarepta has set a benchmark that Solid will now have to meet and ultimately beat, Rama tells investors. The analyst increased his price target on Solid shares to $29 from $10 but reiterates an Underweight rating on the stock, which is up 46% to $42.98 in afternoon trading.
06/20/18
LEER
06/20/18
NO CHANGE
Target $50
LEER
Outperform
Solid Biosciences price target raised to $50 from $28 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Solid Biosciences (SLDB) to $50 from $28, while reiterating an Outperform rating on the stock. The analyst notes that since the company announced that the FDA lifted the clinical hold on SGT-001 for Duchenne muscular dystrophy on June 18, the stock experienced a boost from a coincidentally timed positive read-through from Sarepta's (SRPT) R&D day on June 19. However, the stock has come down from its recent highs following these two events, which the analyst believes presents another buying opportunity. Schwartz is also raising his PoS to 55% from 30% and assuming that Solid Biosciences receives a priority review voucher and sells it for $100M.
06/25/18
NOMU
06/25/18
NO CHANGE
Target $57
NOMU
Buy
Solid Biosciences price target raised to $57 from $37 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target on Solid Biosciences (SLDB) to $57 from $37 after Sarepta (SRPT) presented key biopsy data showing biochemical success of the AAV/microdystrophin approach, which Solid is also investigating. Marai maintains his Buy rating on Solid Biosciences shares.
09/06/18
FBCO
09/06/18
INITIATION
Target $38
FBCO
Neutral
Solid Biosciences initiated with a Neutral at Credit Suisse
Credit Suisse analyst Martin Auster started Solid Biosciences with a Neutral rating and $38 price target. The analyst notes that the company's DMD gene therapy, SGT-001, has clear mechanistic rationale and is well supported by preclinical proof-of-concept. Auster anticipates clinical differentiation, time to market, and durability will be among the most meaningful arbiters of value among the three clinical stage DMD gene therapy products and expects longer term data to refine his thinking and modeling assumptions.
SRPT Sarepta
$141.92

-6.79 (-4.57%)

09/24/18
NEED
09/24/18
NO CHANGE
Target $196
NEED
Buy
Sarepta price target lowered to $196 from $204 at Needham
Needham analyst Chad Messer lowered his price target on Sarepta to $196 after the negative opinion on its eteplirsen drug from the Committee for Medicinal Products for Human Use in Europe. The analyst says that while disappointing, it was not unexpected based on the regulators' previous feedback, adding that the company will now seek more information from the EMA on how to proceed with the program. Messer keeps his Buy rating on Sarepta longer term, noting the company is making "progress with its other exon skipping DMD therapies" and pushing forward into the gene therapy field.
09/24/18
BTIG
09/24/18
NO CHANGE
Target $190
BTIG
Buy
Sarepta one step closer to gene therapy trial with FDA lifting hold, says BTIG
BTIG analyst Timothy Chiang said the FDA lifting its clinical hold on Sarepta's micro-dystrophin gene therapy program for the treatment of Duchenne Muscular Dystrophy moves the company one step closer to beginning its registrational study in 24 patients. The analyst, who expects additional biomarker data to be presented in early October on the four patients that have been dosed with its AAVrh74 micro-dystrophin gene therapy program, maintains a Buy rating and $190 price target on Sarepta shares.
09/26/18
RBCM
09/26/18
NO CHANGE
Target $200
RBCM
Outperform
Sarepta price target raised to $200 from $187 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Sarepta to $200 and kept his Outperform rating. The analyst says his discussions with the company's senior management have left him "even more impressed with their commercial and clinical execution, strong focus on maintaining competitive positioning in development and manufacturing, and commitment to cement their gene therapy leadership role". Abrahams also anticipates a "favorable supportive data" for the microdystrophin gene therapy program at next week's WMS event, with the pivotal plans for the program remaining on track toward FDA feedback later this year and dosing before year-end.
10/01/18
CANT
10/01/18
INITIATION
Target $217
CANT
Overweight
Sarepta initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Sarepta Therapeutics with an Overweight rating and $217 price target.

TODAY'S FREE FLY STORIES

TEX

Terex

$35.29

-0.3 (-0.84%)

19:01
02/22/19
02/22
19:01
02/22/19
19:01
Hot Stocks
Terex to sell Demag Mobile Cranes business to Tadano for $215M enterprise value »

Terex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CZR

Caesars

$9.05

-0.37 (-3.93%)

18:34
02/22/19
02/22
18:34
02/22/19
18:34
Hot Stocks
Canyon Partners: Caesars shareholders' value best served by open sale process »

Canyon Partners issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$20.85

0.17 (0.82%)

, BA

Boeing

$424.05

6.57 (1.57%)

18:11
02/22/19
02/22
18:11
02/22/19
18:11
Periodicals
Brazilian judge suspends Embraer-Boeing deal talks, Reuters reports »

A Brazilian judge…

ERJ

Embraer

$20.85

0.17 (0.82%)

BA

Boeing

$424.05

6.57 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 14

    Mar

  • 28

    May

BXG

Bluegreen Vacations

$14.47

0.55 (3.95%)

18:02
02/22/19
02/22
18:02
02/22/19
18:02
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SM

SM Energy

$16.88

-0.13 (-0.76%)

17:57
02/22/19
02/22
17:57
02/22/19
17:57
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy's higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$37.22

-1.15 (-3.00%)

17:47
02/22/19
02/22
17:47
02/22/19
17:47
Syndicate
Breaking Syndicate news story on AutoNation »

AutoNation files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

TSLA

Tesla

$294.60

3.42 (1.17%)

, NSANY

Nissan

$0.00

(0.00%)

17:42
02/22/19
02/22
17:42
02/22/19
17:42
Periodicals
Tesla's Model 3 was the highest-selling EV globally in 2018, Verge reports »

Tesla's (TSLA) Model…

TSLA

Tesla

$294.60

3.42 (1.17%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFU

InfuSystem

$4.15

0.04 (0.97%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
InfuSystem announces settlement of derivative lawsuit »

InfuSystem Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALU

Kaiser Aluminum

$108.22

-1.9 (-1.73%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
Kaiser Aluminum names Neal West as new CFO »

Kaiser Aluminum announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$14.35

0.19 (1.34%)

17:00
02/22/19
02/22
17:00
02/22/19
17:00
Hot Stocks
Alder Biopharmaceuticals submits eptinezumab BLA to FDA »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

RF

Regions Financial

$16.24

-0.01 (-0.06%)

16:59
02/22/19
02/22
16:59
02/22/19
16:59
Syndicate
Breaking Syndicate news story on Regions Financial »

Regions Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

HL

Hecla Mining

$2.59

-0.145 (-5.31%)

16:58
02/22/19
02/22
16:58
02/22/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

, CELG

Celgene

$89.15

0.54 (0.61%)

16:52
02/22/19
02/22
16:52
02/22/19
16:52
Hot Stocks
Bristol-Myers files proxy statement in connection with proposed Celgene merger »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

CELG

Celgene

$89.15

0.54 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

  • 28

    May

TEN

Tenneco

$36.29

0.76 (2.14%)

16:48
02/22/19
02/22
16:48
02/22/19
16:48
Earnings
Tenneco sees FY19 revenue growth up 4%-5%, consensus $4.65B »

The company expects 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

TEN

Tenneco

$36.29

0.76 (2.14%)

16:46
02/22/19
02/22
16:46
02/22/19
16:46
Earnings
Tenneco reports preliminary Q4 revenue $4.3B, consensus $4.3B »

Sees FY18 EPS "near…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XRX

Xerox

$31.50

0.16 (0.51%)

16:44
02/22/19
02/22
16:44
02/22/19
16:44
Conference/Events
Xerox management to meet with Loop Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TWTR

Twitter

$31.70

0.94 (3.06%)

16:38
02/22/19
02/22
16:38
02/22/19
16:38
Hot Stocks
Twitter board member Evan Williams to step down at end of month »

On February 22, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

ALLY

Ally Financial

$26.95

-0.07 (-0.26%)

16:34
02/22/19
02/22
16:34
02/22/19
16:34
Hot Stocks
Ally Financial CEO sells over 97,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.